Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf
Zhongqiu Zhang(Washington University in St. Louis), Ming You(Houston Methodist), Andrew D. Hamilton(New York University), Elizabeth Kastens, Gongjie Liu(Hebei University), Saı̈d M. Sebti(Virginia Commonwealth University), Laura E. Lantry(The Ohio State University), Yian Wang(Hunan Normal University), Ronald A. Lubet(National Cancer Institute)
Cited by 33
Related Papers
TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth
|Cell|2006|1.4k
Neoantigen vaccine: an emerging tumor immunotherapy
|Molecular Cancer|2019|718
Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
|New England Journal of Medicine|1995|522
Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI-298
|Journal of Bone and Mineral Research|2000|360
A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response
|Nature Communications|2020|246